May 05, 2017
2 min watch
Save
This article is more than 5 years old. Information may no longer be current.
VIDEO: Pembrolizumab improves overall survival in nonsmall cell lung cancer
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
SAN DIEGO — Patients with PD-1 positive nonsmall cell lung cancer who were treated with pembrolizumab had improved overall survival and progression-free survival, Brian Lewis, MD, MPH, from Tulane University, told Healio Internal Medicine at the 2017 ACP Internal Medicine annual meeting.
In addition, Lewis discussed treatment modalities for head and neck cancer, prostate cancer, breast cancer and melanoma and their overall benefits and risks. He also noted that olanzapine improved vomiting and nausea control with minimal toxicity and adverse effects in chemotherapy-induced vomiting and nausea.